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To the Editor: We thank Dr E. Chantelau and Dr C. Currie
for their interest [1, 2] in our findings [3], which we
consider important because they are from a long-term
randomised study that avoids the many limitations of
retrospective database registry studies. They mainly com-
mented on the power of the study and the possibility of
performing post hoc sub-analyses. We would like to
address their assertions, which we believe to be incorrect
or misleading.
We strongly disagree with Dr Chantelau’s suggestion
that the study was underpowered to detect changes in the
rate of progression of diabetic retinopathy (DR) [1]. The
sample size and power for the study were calculated based
on these assumptions: a 20% 5 year background event rate;
a non-inferiority margin of 10% (i.e. 50% of the back-
ground rate of 20%); approximately 60% of the randomised
participants evaluable; and the two treatments being
equivalent. Statistical power considerations are only rele-
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size. On completion, the non-inferiority hypothesis will either
be accepted or rejected, depending on the actual outcome
observed, and the pre-study power assumption is no longer
relevant. Nevertheless, had a 5 year background event rate of
15% been projected (our observed rates were 14.2% and
15.7% in the insulin glargine [A21Gly,B31Arg,B32Arg
human insulin] and neutral protamine Hagedorn [NPH]
insulin groups, respectively), with a non-inferiority margin
of 7.5% (i.e. 50% of the background 15% rate) and a sample
size that is the same as that of the per protocol population, the
study would have had 81% power to demonstrate equiva-
lence. Hence, the study was not underpowered.
Dr Chantelau also questioned the low frequency of DR
at study entry (15.6% and 12.1% of patients reporting a
medical history of DR in the insulin glargine and the NPH
insulin groups, respectively; Table 1 of [3]), and objected to
pooling patients with and without DR at baseline in
assessing progression. Regarding the baseline prevalence
of DR, Table 1 of our paper [3] also shows the frequency of
DR based on grading of the baseline fundus photographs. By
using this more sensitive measurement, a substantial propor-
tion of patients were shown to have DR (~61% in both
groups). Pooling patients with no DR and those with non-
proliferative DR is appropriate when analysing, as we did, the
prevalence of worsening by at least three steps on the Early
Treatment Diabetic Retinopathy Study (ETDRS) retinopathy
severity scale. To illustrate this, in the DCCT, this outcome
was observed at 6 years in the primary prevention cohort (no
DR) in 35% and 11% of the conventional and intensive
treatment groups, respectively. The corresponding rates in the
secondary prevention cohort (mild to moderate non-
proliferative DR) were similar—31% and 11%, respectively
[4]. In a subset of 1919 UK Prospective Diabetes Study
(UKPDS) patients with appropriate photographs, the 6 year
prevalence of worsening by three steps or more was 17.4%
in 1216 patients without DR at baseline and 18.5% in 701
patients with non-proliferative DR [5].
Dr Currie [2] questions the selection of the patient
population and the exclusion of established proliferative
DR in the study, comments on the protective effects of
metformin against cancer, proposes multiple arbitrary post
hoc subgroup analyses, and notes that insulin glargine and
NPH insulin resulted in similar glycaemic control. We
believe that the population selected is indeed the population
that should be studied, as it represents the majority of
patients with type 2 diabetes treated with insulin who are
seen in clinical practice. The entrance criteria allowed
inclusion of a wide range of patients previously treated with
human basal insulin, with or without regular insulin and
oral agents; the resulting population closely matches that
seen in clinical practice. The entry criteria did specify a
particular range of DR, to assure a population in which
assessment of the primary outcome would be most
effective. The observed event rate for progression of three
or more steps in ETDRS score in this study was ~15% at
5 years [3], and was similar to the rates in the UKPDS and
DCCT [4, 5], as described above. Therefore, the suggestion
that ‘… these patients could be those patients least likely to
develop more severe visual loss ...’ is incorrect.
Inclusion of patients with advanced forms of DR to assess
progression, as Dr Currie suggested, is highly unreliable. In
this study, no statistically significant difference in the
development of proliferative DR was observed between the
twogroups,despiteagreaterfrequencyofthehighestcategory
of non-proliferative DR—in which progression of prolifera-
tive DR is most likely—at entry in the insulin glargine group.
The comparison of our randomised trial with a retro-
spective analysis on metformin and cancer is inappropriate.
The percentage of patients using metformin was similar in
both groups in this study (41% at baseline in the glargine
group vs 42% with NPH, and 18% started after random-
isation in the glargine group vs 16% with NPH) [3];
therefore, an imbalance of the effects of metformin could
not have contributed to the findings. Furthermore, the
publication authored by Currie et al. [6] and cited in his
letter [2] actually demonstrated no increase in the frequency
of cancer with insulin glargine compared with other
insulins. There is no basis for Dr Currie’s speculative
statement that ‘Akin to the safety issue with respect to
cancer, it could be that insulin glargine does not trigger the
[retinal] pathology, but, rather, promotes or accelerates
the pathological process.’ Moreover, the question of the
potential protective effects of metformin against cancer is
difficult to evaluate in epidemiological analyses such as the
ones Dr Currie cites, because of the tendency for metformin
to be prescribed for younger and healthier patients.
Regarding cancer risk with different insulins, our study is
particularly relevant as it is the only randomised study to
compare insulin glargine with human insulin, and because
it shows no trend towards a greater risk of neoplasia with
insulin glargine [7]. Recently published expert statements
and objective criticisms have highlighted the possibilities
for bias inherent in epidemiological, non-randomised
comparisons of treatments [8–10].
The multiple subgroup analyses suggested by Dr Currie
seem ill-advised for a randomised trial, in that (1) the
diminished sample sizes of the subsets, with consequently
much wider confidence intervals for statistical testing,
weaken the conclusions that can be drawn; and (2) multiple
post hoc analyses increase the chance of ‘uncovering’
findings that are statistically significant but spurious. Such
post hoc sub-analyses can generate hypotheses, but neither
provide final answers nor put to bed any lingering concerns.
Dr Currie notes that the slightly higher level of HbA1c
observed with insulin glargine compared with NPH insulin
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states the retinal primary objective and emphasises that
testing differences in glycaemic control between the two
insulins was not one of the study objectives. The intention
was for glycaemic control to be as similar as possible in the
two groups, despite insulin glargine being given once daily
and NPH insulin twice daily, to avoid confounding the
interpretation of the retinal outcomes. The requirement that
NPH insulin be given twice daily vs once daily for insulin
glargine actually provides a bias in favour of NPH insulin
in titration of dosage. The small difference (0.2%) at study
end in favour of NPH insulin is, therefore, not surprising. In
any case, the upper bound of the two-sided 95% confidence
interval for HbA1c treatment difference was 0.35%, which
is within the non-inferiority margin of 0.4% conventionally
accepted as a basis for clinical equivalence in efficacy of
HbA1c between two treatments. This difference may be
important mainly in strengthening the finding that retinop-
athy was not adversely affected by use of insulin glargine
vs NPH insulin, despite slightly higher mean glucose.
Finally, concerning hypoglycaemia, this study confirms
findings from many other studies, which have consistently
found a lower incidence of hypoglycaemia with insulin
glargine treatment than with NPH insulin with otherwise
similar regimens and at similar levels of glycaemic control
[11–18].
In summary, we believe that the assertions made in these
two letters are speculative and misguided. Our findings and
conclusions are based on the largest and longest randomised
trial comparing two types of insulin. The study design was
appropriate to address concerns about the effects that insulin
glargine might have on the progression of diabetic retinop-
athy, and the conclusions are well supported. We are
confident that the reassuring findings and conclusions are
correct as reported.
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